APP and early-onset autosomal dominant Alzheimer disease: For example, for Alzheimer’s disease the activators or potentiators of ADAM10 activity might be useful to increase non-amyloidogenic processing of APP thus decreasing amyloid plaque formation in CNS (Bandyopadhyay et al., 2007; Fahrenholz, 2007; Lichtenthaler, 2011; Postina, 2012; Manzine et al., 2019).